Jaguar Health Reports Second Quarter 2024 Financial Results
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net...
Month: August 2024
Compassion Center Expresses Gratitude to Rebecca Siewert of N.W. Classic and Woodburn Property Management for Highlighting Housing Disparities in Oregon
Compassion Center, headquartered in Hillsboro, Oregon, is a pioneer in integrative healthcare, dedicated to improving global quality of life through...
Vytalize Health Named Fastest-Growing Private Company in America by Inc. Magazine
Company Ranks No. 1 on the Prestigious Inc. 5000 Across All Industries After Achieving $1.5 Billion in Revenue for 2023...
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”)...
Crescent Innovations reports strong interest in asset sale
WESTFORD, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Crescent Innovations Inc. reports that activity surrounding sale of its joint, bone...
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
ROSCREA, Ireland and FREIBURG, Germany, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed...
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --...
Intelligent Bio Solutions Inc. Highlights Growing Need for Drug Testing Solutions in Key Industries
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ: INBS) provides an overview of the increasing...
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™...
Ocean Drive Plastic Surgery Introduces Revolutionary Internal Sports Bra Procedure for Athletes and Fitness Enthusiasts
Dr. Alan Durkin, a dual board-certified plastic and reconstructive surgeon and the founder of Ocean Drive Plastic Surgery in Vero...
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone...
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of...
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10...
Notice of Nexstim Plc’s Half-Year Report H1 2024
Press release, Helsinki, 13 August 2024 at 3 PM (EEST) Notice of Nexstim Plc’s Half-Year Report H1 2024 Nexstim Plc...
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...